Show simple item record

dc.contributor.authorZeng, Wenqien_US
dc.contributor.authorGillis, Tammyen_US
dc.contributor.authorHakky, Michaelen_US
dc.contributor.authorDjoussé, Lucen_US
dc.contributor.authorMyers, Richard Hen_US
dc.contributor.authorMacDonald, Marcy Een_US
dc.contributor.authorGusella, James Fen_US
dc.date.accessioned2011-12-29T21:02:24Z
dc.date.available2011-12-29T21:02:24Z
dc.date.copyright2006en_US
dc.date.issued2006-9-7en_US
dc.identifier.citationZeng, Wenqi, Tammy Gillis, Michael Hakky, Luc Djoussé, Richard H Myers, Marcy E MacDonald, James F Gusella. "Genetic analysis of the GRIK2 modifier effect in Huntington's disease" BMC Neuroscience 7:62. (2006)en_US
dc.identifier.issn1471-2202en_US
dc.identifier.urihttp://hdl.handle.net/2144/2524
dc.description.abstractBACKGROUND: In Huntington's disease (HD), age at neurological onset is inversely correlated with the length of the CAG trinucleotide repeat mutation, but can be modified by genetic factors beyond the HD gene. Association of a relatively infrequent 16 TAA allele of a trinucleotide repeat polymorphism in the GRIK2 3'UTR with earlier than expected age at neurological onset has been suggested to reflect linkage disequilibrium with a functional polymorphism in GRIK2 or an adjacent gene. RESULTS: We have tested this hypothesis by sequencing all GRIK2 exons, the exon-flanking sequences and 3'UTR in several individuals who were crucial to demonstrating the modifier effect, as they showed much earlier age at neurological onset than would be expected from the length of their HD CAG mutation. Though ten known SNPs were detected, no sequence variants were found in coding or adjacent sequence that could explain the modifier effect by linkage disequilibrium with the 16 TAA allele. Haplotype analysis using microsatellites, known SNPs and new variants discovered in the 3'UTR argues against a common ancestral origin for the 16 TAA repeat alleles in these individuals. CONCLUSION: These data suggest that the modifier effect is actually due to the TAA repeat itself, possibly via a functional consequence on the GRIK2 mRNA.en_US
dc.description.sponsorshipUS Public Health Service (NS16367); Huntington Disease Society of America's Coalition for the Cure; Harvard Center for Neurodegeneration and Repairen_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2006 Zeng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_US
dc.titleGenetic Analysis of the GRIK2 Modifier Effect in Huntington's Diseaseen_US
dc.typearticleen_US
dc.identifier.doi10.1186/1471-2202-7-62en_US
dc.identifier.pubmedid16959037en_US
dc.identifier.pmcid1618398en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2006 Zeng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2006 Zeng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.